openPR Logo
Press release

Nonalcoholic Steatohepatitis (NASH) Market is Expected to Reach US$ 20.0 Billion by 2025

05-03-2017 10:30 AM CET | Health & Medicine

Press release from: Market Research Engine Research Reports

New York, May 02: Market Research Engine has published a new report titled as “Non-Alcoholic Steatohepatitis (NASH) Market by Therapeutics (GFT505, Obeticholic Acid (INT-747), Liraglutide (Victoza) and Simtuzumab, Vitamin E, Pioglitazone, Placebo) - Global Industry Analysis, Trends and Forecast 2016 - 2025”

Global Non-Alcoholic Steatohepatitis (NASH) market is expected to cross US$ 20.0 Billion by 2025 growing at a CAGR of more than 10.0% during given forecast period from 2016-2025.

Browse Full Report: https://www.marketresearchengine.com/reportdetails/non-alcoholic-steatohepatitis-nash-market

Nonalcoholic Steatohepatitis (NASH) is a disease which occurs in the people who are non alcoholic. The liver damage that is caused in patients is histologically indistinguishable from alcoholic hepatitis. The people suffering from NASH are having fats in the liver along with inflammation and damage. Most people suffering from NASH are not aware of the disease and people feel well. This is a severe form of syndrome and often leads to cirrhosis. People suffering from obesity, dyslipidemia, and glucose intolerance are more prone to NASH. Insulin resistance is found in most of the patients. Most of the patients are asymptomatic. In order to confirm the disease Biopsy is essential. The treatment is done by eliminating the risk factors. The majority of the people in the developed countries suffer from the disease, North America is presumed to be containing the majority of the people suffering from NASH. People suffering from NASH are recommended to go for weight reduction, take a balanced and healthy diet and have good physical activity.

The major driving factors of Nonalcoholic Steatohepatitis (NASH) market are as follows:

1. There is a great increase in the cycles of the clinical trials with increased success rates. Hence there are increased chances of getting a commercial approval by 2017.

The restraining factors of Nonalcoholic Steatohepatitis (NASH) market are as follows:

1. The unexplained and complex physiological structure.
2. Inefficient diagnostics technology which lengthen the commercialization of NASH therapeutics.

The Nonalcoholic Steatohepatitis market is segmented on the lines of its Therapeutics such as GFT505, Obeticholic Acid (INT-747) Simtuzumab and Liraglutide (Victoza)Vitamin EPioglitazonePlacebo. The Nonalcoholic Steatohepatitis market geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa.

This report provides:

1) An overview of the global market for Non alcoholic Steatohepatitis and related technologies.

2) Analyses of global market trends and projections of compound annual growth rates (CAGRs) through 2025.

3) Identifications of new market opportunities and targeted promotional plans for Non alcoholic steatohepatitis market.

4) Discussion of research and development, and the demand for new products and new applications.

5) Comprehensive company profiles of major players in the industry.

REPORT SCOPE:

The scope of the report includes a detailed study of global and regional markets for various types of Non alcoholic steatohepatitis with the reasons given for variations in the growth of the industry in certain regions. The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market.

Nonalcoholic Steatohepatitis market is segmented into therapeutic types and geography.

BY THERAPEUTICS

GFT505
Obeticholic Acid (INT-747)
Simtuzumab and Liraglutide (Victoza)
Pioglitazone
Placebo
Vitamin E

BY GEOGRAPHY

North America
Europe
Asia-Pacific
LAMEA

Reasons to Buy this Report:

1) Obtain the most up to date information available on all active and planned Nonalcoholic steatohepatitis industry globally.

2) Identify growth segments and opportunities in the industry.

3) Facilitate decision making on the basis of strong historic and forecast of Nonalcoholic steatohepatitis industry and unit capacity data.

4) Assess your competitor’s refining portfolio and its evolution.

About MarketResearchEngine.com

Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact

Company Name: Market Research Engine
Contact Person: John Bay
Email: john@marketresearchengine.com
Phone: +1-855-984-1862, +91-860-565-7204
Country: United States
Website: https://www.marketresearchengine.com/

Address: 3422 SW 15 Street, Suite #8942, Deerfield Beach, FL 33442, United States

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Nonalcoholic Steatohepatitis (NASH) Market is Expected to Reach US$ 20.0 Billion by 2025 here

News-ID: 521277 • Views:

More Releases from Market Research Engine Research Reports

Textile Chemicals Market is Expected to Cross 13.5 Million Tons Globally by 2024
The global textile chemicals market by product is segmented assurfactants, desizing agents, colorants & auxiliaries, coating & sizing chemicals, yarn lubricants and finishing agents. According to its applications the market is further segmented in to home furnishing, apparels, industrial and others.The market segments in terms of geographical regions include North America, Europe, Asia-Pacific and Rest of the World(ROW). Browse Full Report @: https://www.marketresearchengine.com/reportdetails/textile-chemicals-market How Big is the Global Textile Chemicals Market? Global textile
Paints and Coatings Market Is Expected to Grow $153.0 Billion by 2020
The paint and coating market segmented in High Solids/Radiation Cure, Powder Coatings, Waterborne Coatings, and Solvent Borne Technologies. Also for the automotive sector it segmented for Aviation, Medical & Healthcare, Residential, Commercial uses. Browse Full Report @: https://www.marketresearchengine.com/reportdetails/paints-and-coatings-market How Big is the Global Paints and Coatings Market? The global paints and coatings market is expected to reach $125.0 billion by the end of 2015 and further increase to $153.6 billion by 2020, at
Ceiling Tiles Market is Expected to Cross US$ 43 Billion Globally By 2023
This market study analyses the market by its value chain. Value chain analysis starts with the analysis of feedstock products and ends with the analysis of end-user industry. The report uses “Market Attractiveness Analysis” and “Porter’s Five Forces Model” to analyze the diverse factors affecting the expansion of the market. Browse Full Report @: https://www.marketresearchengine.com/reportdetails/ceiling-tiles-market How Big is the Global Ceiling Tiles Market? The Global Ceiling Tiles Market was valued at US$
Pain Management Therapeutics Market is Expected to Exceed US$ 83 Billion by 2024
The pain management therapeutics market is segmented on the lines of its therapeutics, indication and regional. Based on therapeutics segmentation it covers antimigraine agents, non steroidal anti inflammatory drugs, anesthetics, antidepressants, anticonvulsants, opioids and other non narcotic analgesic. Opioidsis further segmented into tramadol, hydrocodones, oxycodaones and others such as methadone, meperidine, fentanyl, codeine, morphine. Based on indication segmentation the pain management therapeutics market covers cancer pain, post operative pain, migraine,

All 5 Releases


More Releases for NASH

NASH Market Insight and Landscape report
Report Snapshot: NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their
IQ4I Research published “Non-alcoholic steatohepataitis (NASH) Pipeline Analys …
“Non-alcoholic steatohepataitis (NASH) Pipeline Analysis” gives comprehensive insights on the various drugs being developed for the treatment of NASH. The report covers all the drugs that are in various phases of development (Discovery, Preclinical & Clinical). The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, antibodies, stem cell therapies, recombinant proteins and RNA-based therapeutics, but excludes symptom relief drugs, generic combinations and supplemental drugs. The report
Growing Prevalence of NASH to Increase Adoption of Therapeutics
"The Report OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" MarketResearchReports.biz has itemized the addition of a new market research report to its report repository. The research publication is titled, “Opportunity Analyzer: NASH - Opportunity Analysis and Forecasts to 2026.” The statistical surveying study is a watchful inspection of the general market
OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026
First described in 1980, nonalcoholic steatohepatitis (NASH) (ICD-10-CM = K75.81) is a condition that develops as a subgroup of nonalcoholic fatty liver disease (NAFLD) when excessive fat buildup is accompanied by liver cell injury and inflammation. NAFLD is defined by excessive fat accumulation in the form of triglycerides (steatosis) in the liver. Progression of this condition to NASH dramatically increases the risk of cirrhosis, liver failure, and hepatocellular carcinoma, and
04-07-2017 | Arts & Culture
Memphia PR
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017. Listening to the Beatles and Jack White growing
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will